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Background: Testicular morphology and immunohistochemical studies have never been reported in genetically
documented adult patients with 5 alpha-reductase type 2 deficiency (5α-R2 deficiency).
Case presentation: We describe the testicular histopathology of a 17-year-old XY subject with 5α-R2 deficiency
caused by the recurrent homozygous Gly115Asp loss of function mutation of the SRD5A2 gene.We also performed
an immunohistochemical analysis in order to further study the relationship between seminiferous tubules structure,
Sertoli cell differentiation and androgenic signaling impairment in this case. We thus evaluated the testicular
expression of the anti-Müllerian hormone (AMH), androgen receptor (AR) and 3β-hydroxysteroid dehydrogenase
(3βHSD). Histological analysis revealed a heterogeneous aspect with a majority (92%) of seminiferous tubules (ST)
presenting a mature aspect but containing only Sertoli cells and devoid of germ cells and spermatogenesis. Focal
areas of immature ST (8%) were also found. Testicular AR and 3βHSD expression were detected in adult male
control, 5α-R2 deficiency and CAIS subjects. However, AMH expression was heterogeneous (detectable only in
few AR negative prepubertal ST, but otherwise repressed) in the 5α-R2 deficiency, conversely to normal adult testis
in which AMH was uniformly repressed and to an adult CAIS testis in which AMH was uniformly and strongly
expressed.
Conclusion: Intratesticular testosterone can repress AMH by itself, independently of its metabolism into
dihydrotestosterone. We also compare our results to the few post pubertal cases of 5α-R2 deficiency with available
histological testicular description, reported in the literature. We will discuss these histological findings, in the
more general context of evaluating the fertility potential of these patients if they were raised as males and were
azoospermic.
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The 46, XY disorders of sex development (DSD) are
presently classified in three main categories [1]: disor-
ders of gonad development such as gonadal dysgenesis,
disorders of androgen biosynthesis and metabolism and
disorders related to androgen sensitivity (the androgen in-
sensitivity syndrome, AIS). Within the second category,
genetic causes have been identified, such as loss of func-
tion mutations of the LH receptor gene (LHCGR), 17β hy-
droxysteroid dehydrogenase deficiency type 3, related to
mutations of the HSD17B3 gene and loss of function mu-
tations of the SRD5A2 gene, responsible for 5α-reductase
type 2deficiencywhich is one of the three 5α-reductase
isoforms expressed in humans [2]. In the third category,
androgen receptor (AR) mutations have been identified in
patients with mild, partial or complete androgen insensi-
tivity syndromes (AIS) [1].
AIS have variable phenotypic presentations, mainly
related to the severity of the deleterious effects of AR
mutations. Indeed, subjects with complete androgen in-
sensitivity (CAIS) present as girls and women with femin-
ine aspect of external genitalia but with absent pubic hair,
blind ending vagina and uterine agenesis. In partial andro-
gen insensitivity syndrome (PAIS) phenotypes, there are
varying degrees of masculinization, ranging from perineo-
scrotal hypospadias to minor forms of male infertility,
more or less associated with gynecomastia, underviriliza-
tion, hypotrophic gonads and micropenis [1].
5α-R2 deficiency phenotype is also variable, ranging
from a complete female phenotype at birth to a more or
less complete virilization of genitalia [3]. In girls with
5α-R2 deficiency, spontaneous virilization occurring at
the onset of puberty usually reveals the condition [3].
In both pubertal and adult subjects with CAIS and 5α-
R2 deficiency, very few studies of testicular histology
showed severely altered spermatogenesis [4,5]. The se-
vere spermatogenesis impairement in CAIS and 5α-R2
deficiency could be related in part to the bilateral crypt-
orchidism [6] found in both conditions, but also by ei-
ther altered levels of testicular testosterone action or the
lack of metabolic activation to a more active androgen
due to mutated 5α-reductase type 2.
An interesting cellular marker of Sertoli cells, used for
the evaluation of the androgen signaling within seminifer-
ous tubules is the anti-Müllerian hormone (AMH). AMH
expression is usually recognized as a marker of differenti-
ation of Sertoli cells and considered to be negatively regu-
lated by androgens at puberty and adulthood [7,8].
The first objective of this work was to evaluate the con-
tribution of testicular testosterone versus its 5α-reduced
metabolite, dihydrotestosterone (DHT), on AMH repres-
sion after puberty and its relation with spermatogenesis.
We, therefore, compared the testicular morphology, as
well as the AR and AMH expression in a postpubertalcase of genetically demonstrated 5α-R2 deficiency with
that of a postpubertal case of CAIS. We also compared
our findings to published data describing the histological
testicular features of post pubertal individuals considered
to be 5α-R2 deficient, but in which the diagnosis was not
genetically confirmed. Finally, we discuss the testicular
histological findings in the more general context of the
fertility potential of these patients in adult life, if they were
assigned to a male gender.
Case presentation
The testicular samples of the 5α-R2 deficiency patient
were obtained immediately after the bilateral gonadec-
tomy performed when she was 17-years-old. The patient
was a post-pubertal XY female with primary amenorrhea,
failure of pubertal breast development and virilization, cli-
toromegaly and bilateral cryptorchidism, with testes lo-
cated in the inguinal canals. This phenotype was related to
a recurrent [3], homozygous, missense deleterious muta-
tion in the exon 2 of the SRD5A2 gene (c.344G > A;
Gly115Asp). The residual 5α-reductase type 2 activity in
cells transfected with this mutant was of less than 0.2%
[9] The detailed clinical and hormonal characteristics
of this patient (testosterone-T: 7.2 ng/mL (normal range
in post-bertal males: 3.5-8.5), DHT: 0.16 ng/mL (0.25-1.1),
FSH:14.5 IU/L (2.7-7.4), LH: 4.2 IU/L (2.6-6.5), AMH: 65
pmol/L (15–89) as well as the results of the pelvic mag-
netic resonance imaging (MRI) have been previously de-
scribed [10].
We comparatively analyzed the testicular histological
aspect of this case with those of a CAIS and in a man
with obstructive azoospermia but normal testicular sperm-
atogenesis (see below). The CAIS patient was an 18-year-
old, XY female, with primary amenorrhea (FSH: 3 IU/L,
LH:18 IU/L) and absent axillary and pubic hair and high
testosterone (19 ng/mL) and AMH (170 pmol/L) levels.
On clinical and ultrasound examinations were observed a
blind ending vagina, absent uterus and bilateral crypt-
orchidism (the left gonad was situated in the pelvis while
the right one was located in the inguinal canal). In this
patient, the diagnosis of CAIS was confirmed by the
identification of a missense mutation in the exon 5 of
the AR gene. This recurrent, loss of function mutation
(c.2194G > A, p.Asp732Asn or D732N upon a previous
classification), has already been reported in several CAIS
patients [11] and its deleterious character has been previ-
ously demonstrated, as functional analysis revealed that
this mutant had lost 95% of the wild-type transcriptional
activity [11].
The testicular sample, used as a normal control, was ob-
tained from a 29-year-old patient, with normal testoster-
one and gonadotropin levels (T: 6.8 ng/mL, FSH: 4.5 IU/L,
LH: 4.2 IU/L, AMH: 33 pmol/L) undergoing testicular
biopsy for obstructive azoospermia. Indeed, for ethical
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in healthy men. However, as already reported, more than
86% of patients with obstructive azoospermia present
normal spermatogenesis on testicular biopsies [12]. For
this patient, the histological analysis of the testicular bi-
opsy showed, as expected, normal structures and ongoing
spermatogenesis within seminiferous tubules.
Histology and immunohistochemistry
All subjects gave their informed written consent to allow
the study of testicular samples. This study was approved
by the corresponding local ethics committees and was in
accordance with the French Bioethics law No.2004-800.
All paraffin samples from the three patients were studied
by the pathologist (SF), without knowledge of the under-
lying conditions. For each sample, testicular morphology
was assessed on haematoxylin-eosin staining, followed
by immunohistochemical analysis for the expression
and localization of AR, AMH and 3β-hydroxysteroid
dehydrogenase (3βHSD). The immunohistochemistry tech-
niques used were previously reported in detail [13-15].
Immunonegative controls were performed substituting pri-
mary antibodies with corresponding preimmune immuno-
globulins from the same species. These sections were all
immune-negative.
Macroscopic aspects
The adult testicular samples used as a control, were har-
vested from testes with intrascrotal localization, presenting
normal volume (18 cm3) and morphology. Macroscopic-
ally, both testes of the patient with 5α-R2 deficiency ex-
hibited a similar hypotrophic aspect. Thus, the left testis
had a 6 cm3 volume and weighted 7 g while the right testis
volume was 7 cm3 and weighted 7 g. The testicular sam-
ples of the patient with CAIS obtained after bilateral go-
nadectomy, exhibited similar size (11 and 9 cm3) and
macroscopic aspect than the 5α-R2 deficiency patient’s
testis.
Histological aspects
Haematoxylin-eosin stained paraffin sections from the
adult testicular biopsy showed large seminiferous tu-
bules, outlined by spindle-shaped peritubular myoid cells.
All seminiferous tubules contained mature Sertoli cells lin-
ing the basal membrane and ongoing spermatogenesis
(Figure 1A).
In the 5α-R2 deficiency patient’s testis, haematoxylin-
eosin staining revealed heterogeneous seminiferous tu-
bules, surrounded by few peritubular myoid cells and a
thickened basement membrane (Figure 1B). The major-
ity of these seminiferous tubules displayed central lu-
mina and normal diameters for the age. They contained
two types of Sertoli cells: either mature Sertoli cells, with
limited borders and visible nucleoli, or involuting Sertolicells, with lobulated shapes, irregular borders and incon-
spicuous nucleoli (Figure 1B). Besides these mature tu-
bules, there was a focal area of seminiferous tubules,
representing 8% of the seminiferous tubules, with small
tubular diameters and lack of central lumina consistent
with an immature, prepubertal pattern (Figure 1B, thick
black arrow). These immature seminiferous tubules were
characterized by a pseudostratified distribution of Sertoli
cells; this aspect was similar to the testicular histology
described by Regadera et al. [16] in patients with secretory
azoospermia caused by hypogonadotropic hypogonadism.
Some prepubertal seminiferous tubules also contained few
spermatogonia. In order to specify the nature of Sertoli
cells histological aspects in this 5α-R2 deficiency patient,
we performed a selected magnification (Figure 2). We thus
observed some seminiferous tubules, with flattened as-
pect, where Sertoli cells exhibited an oncocytic cytoplasm
(Figure 1B, white arrow and Figure 2, black arrow). The
interstitial space in this sample contained large areas
of Leydig cells presenting an intense eosinophilic and
granular cytoplasm and single round nuclei, consistent
with Leydig cell hyperplasia (Figure 1B, thin black arrow).
In the CAIS patient, the testicular sample stained with
haematoxylin-eosin showed dispersed seminiferous tu-
bules with a homogeneous immature aspect characterized
by small tubular diameters and lack of central lumina. All
seminiferous tubules were surrounded by a thickened
basal membrane (Figure 1C, thick black arrow) and by
peritubular myoid cells. The majority of seminiferous tu-
bules in this testicular sample contained exclusively Sertoli
cells with a pseudostratified distribution, consistent with
immature seminiferous tubules [16]. Spermatogenesis was
absent in all seminiferous tubules in this CAIS subject;
spermatogonia were present only in few tubules (data not
shown). Likewise the testicular sample of the 5α-R2 defi-
ciency patient, we observed few seminiferous tubules
containing several Sertoli cells with an oncocytic aspect
(Figure 1C, white arrow). Finally, the interstitial space in
the CAIS testis contained focal areas of important Leydig
cell hyperplasia (Figure 1C, thin black arrow).
Immuno-histochemical studies
To clarify the relationship between abnormal Sertoli cell
differentiation, androgen signaling and spermatogenesis de-
fect, we studied the expression of two Sertoli cell markers,
AR and AMH in testicular sections in both 5α-R2 defi-
ciency and CAIS patients compared to the control sample
(Figure 1, panels D to I).
The AR protein was expressed in Sertoli, Leydig and
peritubular myoid cells in the control adult testis sample
(Figure 1D) in accordance to previous data reported by
us and others [7,8,15]. Similarly, AR was expressed in
Sertoli, Leydig and peritubular myoid cells in both
5α-R2 deficiency (92% of tubules) and CAIS (100% of
Figure 2 Testicular section magnification, on hematoxylin-eosin staining, of the 17 year-old teenager with 5 α-R2 deficiency.
Seminiferous tubules with large diameter and containing only Sertoli cells, surround a flattened section of a tubule, containing Sertoli cells with

























Figure 1 Histological characteristics and immunohistochemical detection for AR, AMH and 3βHSD expression, in testicular
paraffin-embedded sections obtained from a 29 year old human adult with normal testicular structures (Figure 1: panels A, D, G, J),
a 17 year-old teenager with 5 α-R2 deficiency (Figure 1: panels B, E, H, K) and a 18 year-old CAIS teenager (Figure 1: panels C,
F, I, L). Panels A, B, C- histology of testicular samples on haematoxylin-eosin staining. Panel A shows complete spermatogenesis in a
seminiferous tubule section of the normal adult testis; Panel B shows heterogeneous seminiferous tubules (ST), in the 5 α-R2 deficiency,
such as tubules presenting large diameters and lumina(white arrows) and other tubules with small diameter lacking lumina (thick black
arrow); Panel C, shows, in a CAIS patient, used for comparison, a homogeneous pattern, with small diameter, immature STs. In this CAIS
patient, STs are delineated by a thickened basal membrane (thick black arrow). In one ST, Sertoli cells with an oncocytic transformation of
the cytoplasm are indicated (white arrow).The interstitial compartment contains an area of Leydig cell hyperplasia (thin black arrow).
Panels D, E, F- show AR immune detection in testicular sections obtained from the three subjects. AR is immunodetected in Sertoli cells,
Leydig cells and peritubular myoid cells. Panel F evidentiates positive AR immunostaning in ST of the CAIS patient's testicular sample.
Panels G, H, I- show AMH immune detection in STs of the testicular sections obtained from the three subjects. Panels J, K, L- show
3βHSD immune detection in Leydig cells of the testicular sections obtained from the three subjects. Scale bars -50 μm.
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R2 deficiency patient’ testis, the AR immuno-expression
was absent in a minority (8%) of seminiferous tubules,
with a prepubertal aspect.
As previously reported [7,13,17,18], AMH was barely
detected in the normal adult seminiferous tubules with
ongoing spermatogenesis (Figure 1G). In the 5α-R2 defi-
ciency patient’s testis, AMH expression was heteroge-
neous, with no detectable immunostaining in 92% of
tubules with larger lumina and AR expression. However,
AMH was clearly expressed in focal areas (8% of tu-
bules) corresponding to immature tubules with no AR
expression (Figure 1H).
Contrasting with the morphological aspect of the 5α-
R2 deficiency patient’s testis, all seminiferous tubules
studied in the CAIS patient intensively expressed AMH
(Figure 1I). This AMH expression pattern was similar to
those previously described in CAIS patients by many
groups [7,18].
Finally, in order to specify the Leydig cell steroido-
genic status, we also evaluated the 3β-hydroxysteroid de-
hydrogenase (3βHSD) expression by immunostaining
(Figure 1, panels J-L). Positive immunolabeling within
interstitial Leydig cells was observed not only in the nor-
mal adult testicular sample (Figure 1 panel J), but also in
the 5α-R2 deficiency case (Figure 1 panel K) as well as
in the CAIS sample (Figure 1 panel L).
Conclusions
Herein, we report the histological and immunohisto-
chemical testicular analysis of a posptubertal patient
with 5α-R2 deficiency; the diagnostic was considered in
front of the clinical presentation, associated with a high
T/DHT ratio, and confirmed by the genetic analysis,
which revealed a homozyguous missense mutation in
the SRD5A2 gene (c.344G > A; Gly115Asp). The dele-
terious character of this recurrent mutation was clearly
demonstrated by Wigley et al. [9] who showed a 99%
loss of the enzymatic activity of the mutated protein. To
our knowledge, we present the first testicular histological
description in a postpubertal patient, with a genetic con-
firmation of the 5α-R2 deficiency. Indeed, the eight pre-
vious publications (Table 1) describing with more or less
details the testicular histology in postpubertal patients,
putatively affected by this pathology, are relatively old
and lack any information related to patients SRD5A2
gene analysis [5,19-25].
Overall, histological features in those postpubertal pa-
tients with 5α-R2 deficiency seem to be rather heteroge-
neous, varying from complete lack of spermatogenesis to
apparently normal spermatogenesis (Table 1).
The histological analysis of the testicular samples ob-
tained from our patient revealed a heterogeneous aspect
with a wide majority of seminiferous tubules presentinga mature aspect but a severely altered spermatogenesis,
and containing only Sertoli cells. In a minority of semin-
iferous tubules of prepubertal appearance, where Sertoli
cells exhibited a pseudostratified distribution, few germ
cells were identified. Overall, the histological aspect of
our patient’s testicular samples was similar to that de-
scribed by Steger et al. [5], in three postpubertal patients
(Table 1, patients 2, 9 and 10), presenting with clinical
features resembling a 5α-R2 deficiency. The combined
histological study of our case, and the analysis of the
available literature (Table 1) also showed a strong per-
centage of impaired spermatogenesis (7/8, 87%) in crypt-
orchid 5 alpha-reductase type 2 deficiency patients
[5,21,22]. These findings suggest that cryptorchidism by
itself could be deleterious for spermatogenesis. Similarly,
we compared serum dihydrotestosterone (DHT) levels
in subjects with histologically normal spermatogenesis
with those measured in patients presenting with im-
paired spermatogenesis (Table 1). Within the first group
of patients (n = 4), mean DHT levels were of 0.26 ±
0.05 ng/mL whereas in the second group mean DHT
levels were 0.12 ± 0.07 ng/mL. We therefore noticed a
trend toward reduction in serum DHT levels in patients
with impaired spermatogenesis suggesting that a more
severe impairment in 5 alpha-reductase type 2 activity
could also contribute to the spermatogenesis alteration.
Histological analysis of the testicular samples of the
5α-R2 deficiency patient reported here also revealed an
oncocytic transformation of Sertoli cell cytoplasm in
very few seminiferous tubules. This minoritary peculiar
histological feature is similar to that described in several
infertile subjects [26].The pathophysiological significance
of this feature is still unknown, but it remains to be de-
termined whether this oncocytic transformation may be
associated to testis tumor development. Important areas
of Leydig cell hyperplasia were also observed in our case;
such morphological observation has been previously
found in 5α-R2 deficient testis [22,24,25].
Similarly, Leydig cell hyperplasia has been already re-
ported in CAIS postpubertal patients [4], or in men with
Klinefelter syndrome [27]. In all these different patho-
logical conditions, Leydig cell hyperplasia could be related
to chronic Leydig cell stimulation induced by the long-
lasting LH excessive secretion [14,24,27,28]. The risk of
progression of these lesions to a Leydig cell tumor is un-
known in 5α-R2 deficiency but deserves to be monitored
if the testes are preserved.
The immunohistochemical analysis also revealed that in
our patient, the androgen receptor (AR) was expressed in
all three testicular compartments (Sertoli cells, Leydig
cells and peritubular myoid cells), suggesting the possibil-
ity of a global cellular response to the intratesticular tes-
tosterone in this case of 5α-R2 deficiency. Most notably,
AR was expressed in 92% of the seminiferous tubules,









1 14 46,XY Female PA; cryptorchidism 7/NA 20.0/(2.0) 3.6 36 NA SGA [22] (1986)
2 16 46,XY Female NA 38.3/(5.0) NA NA NA PST (1%) [5] (1999)




3 16 46,XY Female 3/ 15.5 1.0/(0.5) 5.8 29 NA SCA [22] (1986)
PA; PPH; 4 cm phallus SGA
cryptorchidism§ SCO
4 16 46,XY F emale PA; PPH; 3 cm phallus
cryptorchidism
11/ 22 4.5/NA 11.4 34.5 NA Normal [22] (1986)
5 16 46,XY Female PA; cryptorchidism NA 8.7/(1.0) 9.0 225 NA SGA [22] (1986)
6 17 46,XY Female PA; PPH; 3 cm phallus 3/NA 20/(1.0) 7.2 NA NA SCO [24] (1980)
7 18 46,XY Female PA; PPH; 3 cm phallus 3/NA 56/(3.1) 6.8 NA NA SCO [24] (1980)
8 18 46,XY Female PA; PPH; 1.5 cm phallus 15/NA 5.5/(1.1) 10 39 NA Normal [19] (1980)
9 18 46,XY Female PA; PPH; clitoromegaly
cryptorchidism§
NA 9.0/(1.3) NA NA NA PST (10%) [5] (1999)
SCO (90%)
10 18 46,XY Female PA; PPH; clitoromegaly NA 13.0/(2.0) NA NA NA PST (4%) [5] (1999)
SCO (96%)
11 25 46,XY Female PA; PPH; 3 cm phallus NA NA 11 42 NA Normal [23] (1979)
12 35 46,XY Female PA 8/NA 32.0/(3.2) 6.7 33.5 NA Normal SCO [22] (1986)
13 45 46,XY NA NA NA NA NA NA Normal [25] (1977)
14 65 46,XY Male perineal hypospadias;
6 cm phallus cryptorchidism
NA 40/(4.0) 5.9 38 NA SCO (100%) [21] (1980)
15 NA 46,XY NA NA NA NA NA NA Normal [20] (1982)
Our case 17 46,XY Female PA; PPH; clitoromegaly
cryptorchidism
9/ 8 14.5/(2.0) 7.2 45 Gly115Asp PST (8%) present paper
SCO (92%)
*TV /TW: mean testicular volume in mililiters/ mean testicular weight in grams; **(xULN): ratio between the measured value and the upper limit of normal for the corresponding FSH assay; ***T/DHT ratio: testosterone/
dihydrotestosterone ratio; the ratio cutoff for the diagnosis of 5α-reductase type 2 deficiency was set at 10 [3].
PA: primary amenorrhoea; PPH: poseudovaginal perineoscrotal hypospadias; §For these individuals cryptochidism was not specified in the references, but it was suspected, given the female phenotype; NA:
not available.
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pression was below detectable levels in 8% of the semin-
iferous tubules, specifically those with an immature aspect.
Along this line, it is worth noting that AMH immunode-
tection was rather heterogeneous, as previously reported in
a case of 5α-R2 deficiency with “Sertoli cell only” histology
[5]. We showed that AMH was repressed in the majority
of the seminiferous tubules, whereas AMH was only de-
tectable in immature tubules lacking AR expression. These
results suggest that intratesticular testosterone seems suffi-
cient to repress AMH, when AR is expressed, in spite of
the 5α-R2 deficiency, and thus irrespective of the conver-
sion of testosterone into dihydrotestosterone. The absence
of AMH repression in few seminiferous tubules, in which
AR was lacking, is in accordance with previous data pub-
lished [7,8], supporting the need of AR expression in
Sertoli cells for AMH repression. Interestingly, in our pa-
tient, AMH was repressed in Sertoli cells harboring mature
morphology, even in the absence of germ cells. This sug-
gests that testosterone could exert direct inhibitory effects
on AMH expression, independently from spermatogenesis
initiation [29]. Alternatively, the absence of spermatogonia
in most seminiferous tubules of our patient might have led
to functional alterations in Sertoli cells, disrupting their
ability to synthesize AMH.
In our patient with 5 alpha-Reductase type 2 Defi-
ciency, serum AMH level was within normal range for
postpubertal male as reported in few cases with this con-
dition [30]. This contrasts with the very high serum
AMH levels we observed in our CAIS patient, which
were in line with the increase in AMH levels reported in
adult CAIS patients [31]. This difference in serum AMH
levels in 5 alpha-Reductase type 2 Deficiency versus
CAIS reinforces the hypothesis that testosterone conver-
sion into dihydrotestosterone seems not essential for
AMH repression.
Identification of various spermatogenesis stages in pa-
tients with 5α-R2 deficiency is of importance in the con-
text of sex assignment and fertility preservation. Indeed,
due to recent progress in the assisted reproduction tech-
niques, successful results with testicular sperm extrac-
tion (TESE) and intracytoplasmic sperm injection (ICSI)
are now reported in azoospermic patients, either with
androgen insensitivity [14] or with Klinefelter syndrome
[27]. Concerning 5α-R2 deficient patients, normal sperm-
atogenesis with spontaneous fertility is extremely rare
(two published cases) [32]. On the same way, spermatozoa
detection in the seminal fluid is also a very rare event,
found in only nine 5α-R2 deficient cases [33-35], allowing
either intrauterine insemination of the partner in one case
[33], or an in vitro fertilization by ICSI, as recently re-
ported for two patients [34,35]. Except these uncommon
cases, fertility remains an important issue for 5α-R2 defi-
cient patients, notably those harboring a severe enzymaticdefect that precludes spontaneous parenthood and sperm
recovery in the ejaculate (i.e. azoospermic patients). In
these latter cases, of unknown prevalence, the only fertility
therapeutic possibility could be the testicular sperm ex-
traction (TESE). This therapeutic option seems reasonable
since as indicated above, TESE has been used as a success-
ful therapeutic strategy in a number of patients with non
obstructive azoospermia of various origins, including
those with cryptorchidism [36]. In this context, a detailed
testicular histological analysis is crucial since this is cur-
rently the only reliable method to know if there is sperm-
atozoa in the testis and if spermatozoon are present, to
carry out a cryopreservation for ICSI. Finally, a direct rela-
tionship between the SRD5A2 gene mutation severity and
the presence of spermatozoa still remains an unsolved
question, opening further studies with regards to the prog-
nostic and risk stratification in relation with the severity of
the enzymatic defect.
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